Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics
− Elritercept is a late-stage, potentially best-in-class activin inhibitor designed to treat anemia associated with certain hematologic cancers, including myelodysplastic syndromes and myelofibrosis − Takeda to receive exclusive global license in all territori





